UnitedHealth Group recently experienced significant developments, including the appointment of Stephen J. Hemsley as CEO after Andrew Witty's resignation, and the suspension of its 2025 earnings outlook due to accelerating care activities and higher-than-expected medical costs. These significant internal shifts may have influenced the company's substantial 21% share price decline over the last week. In contrast, the overall market saw a 3.9% rise, highlighting the unique challenges faced by UNH amid market optimism driven by the expected 14% earnings growth in the broader market over the forthcoming years.

We've identified 1 risk for UnitedHealth Group that you should be aware of.NYSE:UNH Earnings Per Share Growth as at May 2025

Find companies with promising cash flow potential yet trading below their fair value.

The recent leadership changes at UnitedHealth Group, alongside the indefinite suspension of its 2025 earnings outlook due to escalating care activities, could further challenge its revenue and earnings growth. This uncertainty might influence investor sentiment, especially against the backdrop of the company's short-term 21% share price decline. Over the longer-term, however, the total shareholder return was 15.93% over the past five years, highlighting the company's resilience in delivering value to investors over time despite recent setbacks.

The company's past year's performance has seen some underperformance compared to the broader US market, which had an 11.6% return, underscoring the pressure from unexpected changes in Medicare dynamics and higher medical costs. These factors could continue to affect UnitedHealth's ability to achieve projected earnings, with existing revenue forecasts suggesting a 9.4% annual growth over the next three years. The share price's recent drop brings it to approximately US$394.51, which is substantially below the consensus analyst price target of US$539.95, indicating potential upside should the company manage to align its growing operational challenges with the expectations built into these valuations.

Upon reviewing our latest valuation report, UnitedHealth Group's share price might be too pessimistic.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Story Continues

Companies discussed in this article include NYSE:UNH.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments